Form 4 for CRDF Cardiff Oncology, Inc.
Accepted 2022-09-19 00:00:00 ET · period of report 2022-09-16 · accession 0001628280-22-025099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-19 | 2022-09-16 | CRDF | Levine James E. | CFO | P - Purchase | $1.56 | +30.0K | 60.0K | +100% | +$46.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-16 | P | A | 30,000 | $1.56 | 60,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.555 to $1.56. Full information regarding the number of shares purcahsed at each separate price can be furnished to the SEC staff upon request. |